keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant sunitinib

keyword
https://www.readbyqxmd.com/read/29935800/developments-in-urologic-oncology-oncoforum-the-best-of-2017
#1
F Gómez-Veiga, A Alcaraz-Asensio, J Burgos-Revilla, J Cózar-Olmo
OBJECTIVE: To put forth new findings of urologic oncology with impact on clinical practice presented during 2017 in the main annual meetings. METHODS: This document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee. RESULTS: Among patients at high risk of recurrent renal cell carcinoma after nephrectomy, adjuvant sunitinib compared to placebo showed a benefit in patients at higher risk of recurrence...
June 20, 2018: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/29877179/kidney-cancer-research-network-of-canada-consensus-statement-on-the-role-of-adjuvant-therapy-after-nephrectomy-for-high-risk-non-metastatic-renal-cell-carcinoma-a-comprehensive-analysis-of-the-literature-and-meta-analysis-of-randomized-controlled-trials
#2
Pierre I Karakiewicz, Emanuele Zaffuto, Anil Kapoor, Naveen S Basappa, Georg A Bjarnason, Normand Blais, Rodney H Breau, Christina Canil, Darrel Drachenberg, Sebastien J Hotte, Claudio Jeldres, Michael A S Jewett, Wassim Kassouf, Christian Kollmannsberger, Luke T Lavallée, Ranjena Maloni, Francois Patenaude, Frédéric Pouliot, M Neil Reaume, Robert Sabbagh, Bobby Shayegan, Alan So, Denis Soulières, Simon Tanguay, Lori Wood, Marco Bandini
INTRODUCTION: The Kidney Cancer Research Network of Canada (KCRNC) collaborated to prepare this consensus statement about the use of target agents as adjuvant therapy in patients with non-metastatic renal cell carcinoma (nmRCC) after nephrectomy. We reviewed the published data and performed a meta-analysis of studies that focused on vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). METHODS: A systematic literature search identified seven trials on adjuvant target therapy in nmRCC...
June 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29868467/advances-and-challenges-on-management-of-gastrointestinal-stromal-tumors
#3
REVIEW
Lin Mei, Wei Du, Michael Idowu, Margaret von Mehren, Sosipatros A Boikos
Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for over 5,000 newly diagnosed cases in the United States. The discovery of activated KIT and PDGFRA mutations and introduction of imatinib revolutionized the treatment strategy and opened up the new era of target therapy for solid tumors. Although surgery remains the primary modality of treatment for curative purpose, almost half of the patients experienced disease recurrence. Tailoring (neo)-adjuvant treatment with imatinib is ongoing to meet the need for an effective therapy...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29784745/updates-to-the-management-of-kidney-cancer
#4
Eric Jonasch
Several updates were made to the 2018 NCCN Guidelines for Kidney Cancer. Adjuvant sunitinib is the first adjuvant therapy to be endorsed by the panel for patients with stage II and III clear cell histology renal cell carcinoma (RCC; category 2B). A promising new treatment-ipilimumab plus nivolumab for patients at intermediate and poor risk in the frontline setting-was added to the guidelines as well. Cabozantinib was added as a first-line option for poor- and intermediate-risk patients with advanced RCC.
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29784193/adjuvant-vascular-endothelial-growth-factor-targeted-therapy-in-renal-cell-carcinoma-a-systematic-review-and-pooled-analysis
#5
REVIEW
Maxine Sun, Lorenzo Marconi, Tim Eisen, Bernard Escudier, Rachel H Giles, Naomi B Haas, Lauren C Harshman, David I Quinn, James Larkin, Sumanta K Pal, Thomas Powles, Christopher W Ryan, Cora N Sternberg, Robert Uzzo, Toni K Choueiri, Axel Bex
CONTEXT: Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC). OBJECTIVE: To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC. EVIDENCE ACQUISITION: A critical review of PubMed/Medline, Embase, and the Cochrane Library in January 2018 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement was performed...
May 18, 2018: European Urology
https://www.readbyqxmd.com/read/29773662/validation-of-the-16-gene-recurrence-score-in-patients-with-locoregional-high-risk-renal-cell-carcinoma-from-a-phase-3-trial-of-adjuvant-sunitinib
#6
Brian I Rini, Bernard Escudier, Jean-Francois Martini, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D Goddard, Phillip G Febbo, Rachel Li, Xun Lin, Olga Valota, Michael Staehler, Robert J Motzer, Alain Ravaud
PURPOSE: Adjuvant sunitinib prolonged disease-free survival (DFS) (hazard ratio [HR] 0.76) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov NCT00375674). The 16-gene Recurrence Score (RS) assay was previously developed and validated to estimate risk for disease recurrence in patients with RCC post-nephrectomy. This analysis further validated the prognostic value of RS assay in patients from S-TRAC and explored association of RS results with prediction of sunitinib benefit...
May 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29726794/ectopic-rhabdoid-meningioma-of-the-orbit-in-a-child-case-report-and-review-of-the-literature
#7
Yağmur Seda Yeşiltaş, Kaan Gündüz, Aylin Okçu Heper, Esra Erden
In August 2016, an 11-year-old boy presented to the authors' institution with a right orbital tumor that was located superotemporally (superolaterally) and adherent to the sclera. The patient's past medical history revealed that he had undergone 2 previous craniotomies elsewhere in June 2008 and July 2010 for a superomedially located orbital lesion that had been histopathologically diagnosed as a neurothekeoma. After the second craniotomy, the patient underwent adjuvant intensity modulated radiotherapy (IMRT) to the right medial orbit...
May 4, 2018: Journal of Neurosurgery. Pediatrics
https://www.readbyqxmd.com/read/29662544/sunitinib-in-the-treatment-of-renal-cell-carcinoma-an-update-on-recent-evidence
#8
REVIEW
Mimma Rizzo, Camillo Porta
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in January 2006, sunitinib represents a key molecule in the treatment of metastatic renal cell carcinoma (mRCC) due to the peculiar molecular pathogenesis of this neoplasm. Over the past 10 years, clinical trials and real-world experiences helped clinicians to understand how, when and for how long to use sunitinib...
August 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29589470/the-merit-of-tyrosine-kinase-inhibitors-in-the-adjuvant-setting-of-high-risk-renal-cell-carcinoma-a-meta-analysis
#9
Hampig Raphael Kourie, Ziad Bakouny, Roland Eid, Fady Gh Haddad, Joseph Kattan
AIM: As no meta-analyses have evaluated tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma (RCC), the aim was to evaluate the benefit of sunitinib and pazopanib in the adjuvant setting. METHODS: This meta-analysis included all Phase III randomized controlled trials evaluating adjuvant sunitinib and pazopanib in high-risk RCC. Primary outcome was the comparison of disease-free survival (DFS) between tyrosine kinase inhibitors and placebo...
April 2018: Future Oncology
https://www.readbyqxmd.com/read/29573266/sorafenib-paradoxically-activates-the-ras-raf-erk-pathway-in-polyclonal-human-nk-cells-during-expansion-and-thereby-enhances-effector-functions-in-a-dose-and-time-dependent-manner
#10
J Lohmeyer, T Nerreter, J Dotterweich, H Einsele, R Seggewiss-Bernhardt
Natural killer (NK) cells play a major role in host immunity against leukaemia and lymphoma. However, clinical trials applying NK cells have not been as efficient as hoped for. Patients treated with rapidly accelerated fibrosarcoma (RAF) inhibitors exhibit increased tumour infiltration by immune cells, suggesting that a combination of RAF inhibitors with immunotherapy might be beneficial. As mitogen-activated protein kinases (MAPKs) such as raf-1 proto-oncogene, serine/threonine kinase (CRAF) regulate NK cell functions, we performed an in-vitro investigation on the potential of clinically relevant short-acting tyrosine kinase inhibitors (TKIs) as potential adjuvants for NK cell therapy: NK cells from healthy human blood donors were thus treated with sorafenib, sunitinib or the pan-RAF inhibitor ZM336372 during ex-vivo expansion...
March 24, 2018: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29522146/the-us-food-and-drug-administration-s-approval-of-adjuvant-sunitinib-for-renal-cell-cancer-a-case-of-regulatory-capture
#11
Bishal Gyawali, Daniel A Goldstein
No abstract text is available yet for this article.
May 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29507530/the-tyrosine-kinase-inhibitor-nilotinib-is-more-efficient-than-mitotane-in-decreasing-cell-viability-in-spheroids-prepared-from-adrenocortical-carcinoma-cells
#12
Elaine Silveira, Isadora Pontes Cavalcante, Jean Lucas Kremer, Pedro Omori Ribeiro de Mendonça, Claudimara Ferini Pacicco Lotfi
Background: New drugs for adrenocortical carcinoma (ACC) are needed because most patients undergo rapid disease progression despite surgery and adjuvant therapy with mitotane. In this study, we aimed to investigate the in vitro effects of different chemotherapy drugs, alone or combined with mitotane, on the viability of adrenocortical carcinoma cells. Methods: Everolimus, sunitinib, zoledronic acid, imatinib and nilotinib cytotoxicity, alone or combined with mitotane were tested on ACC H295R cells in monolayer or spheroid cultures using MTS assays and confocal microscopy...
2018: Cancer Cell International
https://www.readbyqxmd.com/read/29449091/adjuvant-therapies-in-nonmetastatic-renal-cell-carcinoma-a-review-of-the-literature
#13
REVIEW
Marco Bandini, Ariane Smith, Michele Marchioni, Raisa S Pompe, Tristan F Martel, Luca Cindolo, Francesco Montorsi, Shahrokh F Shariat, Alberto Briganti, Anil Kapoor, Umberto Capitanio, Pierre I Karakiewicz
To conduct a review of literature on adjuvant therapy in nonmetastatic renal-cell carcinoma (nmRCC) treated with nephrectomy and to describe the efficacy of adjuvant agents on cancer control outcomes. A review of the literature was performed in January 2018 to identify all studies evaluating adjuvant therapy in patients with nmRCC treated with nephrectomy using PubMed, Embase, Medline, and Cochrane Library databases. The following keywords were used: adjuvant therapy, renal-cell carcinoma, nonmetastatic, targeted molecular therapy, kidney cancer...
June 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29435133/elucidating-mechanisms-of-sunitinib-resistance-in-renal-cancer-an-integrated-pathological-molecular-analysis
#14
Henriett Butz, Qiang Ding, Roy Nofech-Mozes, Zsuzsanna Lichner, Heyu Ni, George M Yousef
Upon sunitinib treatment of metastatic renal cell carcinoma patients eventually acquire resistance. Our aim was to investigate microRNAs behind sunitinib resistance. We developed an in vivo xenograft and an in vitro model and compared morphological, immunhistochemical, transcriptomical and miRNome data changes during sunitinib response and resistance by performing next-generation mRNA and miRNA sequencing. Complex bioinformatics (pathway, BioFunction and network) analysis were performed. Results were validated by in vitro functional assays...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29435010/chloroquine-potentiates-the-anticancer-effect-of-sunitinib-on-renal-cell-carcinoma-by-inhibiting-autophagy-and-inducing-apoptosis
#15
Man-Li Li, You-Zhi Xu, Wen-Jie Lu, Yong-Huai Li, Shi-Sheng Tan, Hong-Jun Lin, Tian-Ming Wu, Yan Li, Si-Ying Wang, Ying-Lan Zhao
Sunitinib based adjuvant chemotherapy combined with chloroquine (CQ) for the treatment of renal cell carcinoma (RCC) is in clinical trials; however, its anti-RCC effect and the mechanism remain unclear. In the present study, the anti-RCC effect of sunitinib with CQ and the underlying mechanism was investigated. An MTT assay demonstrated that CQ enhanced the proliferation inhibitory effect of sunitinib against the OS-RC-2 RCC cell line. CQ inhibited sunitinib-induced autophagy in OS-RC-2, which was evidenced by the inhibition of autophagic vacuoles, acidic vesicular organelle formation, light chain 3 (LC3)-II recruitment to the autophagosomes and the conversion of LC3-I to LC3-II, as induced by sunitinib...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29433972/re-adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma-after-nephrectomy
#16
Amirali Salmasi, Izak Faiena, Alexandra Drakaki, Allan J Pantuck
No abstract text is available yet for this article.
February 9, 2018: European Urology
https://www.readbyqxmd.com/read/29409504/unusual-progression-of-renal-cell-carcinoma-with-carcinomatosis-peritoneii-and-krukenberg-tumour-and-alopecia-with-sunitinib-therapy-in-young-female
#17
Manoj Pandey, Mahendran Ramasamy, Mridula Shukla
BACKGROUND: Sunitinib is a multiple receptor tyrosine kinase inhibitor (TKI) used for the treatment of renal cell carcinoma (RCC). It increases the median survival considerably with minimum side effects. Alopecia is one of the rare side effects. Metastasis to the ovary is also rare. We report a case of RCC metastasizing to the ovary developing alopecia early on starting sunitinib. CASE PRESENTATION: A 22-year-old hypothyroid girl underwent right radical nephrectomy for T2 N0 RCC...
February 6, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29374054/immune-biomarkers-predictive-for-disease-free-survival-with-adjuvant-sunitinib-in-high-risk-locoregional-renal-cell-carcinoma-from-randomized-phase-iii-s-trac-study
#18
Daniel J George, Jean-François Martini, Michael Staehler, Robert J Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, Sherry Li, Michelle Casey, Brigitte Laguerre, Hardev S Pandha, Allan J Pantuck, Anup Patel, Maria J Lechuga, Alain Ravaud
Purpose: Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov number NCT00375674). A prospectively designed exploratory analysis of tissue biomarkers was conducted to identify predictors of treatment benefit. Experimental Design: Tissue blocks were used for immunohistochemistry (IHC) staining of programmed cell death ligand 1 (PD-L1), CD4, CD8, and CD68. DFS was compared between < versus ≥ median IHC parameter using the Kaplan-Meier method...
April 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29274030/fatigue-among-patients-with-renal-cell-carcinoma-receiving-adjuvant-sunitinib-or-sorafenib-patient-reported-outcomes-of-ecog-acrin-e2805-trial
#19
Fengmin Zhao, David Cella, Judith Manola, Robert S DiPaola, Lynne I Wagner, Naomi S B Haas
BACKGROUND: E2805 was a phase III trial to test whether adjuvant sunitinib or sorafenib could improve disease-free survival compared to placebo in patients with renal cell carcinoma. Patient-reported outcomes (PRO), focusing on fatigue, were evaluated as a secondary endpoint. PATIENTS AND METHODS: A total of 463 patients participated in the PRO study. Fatigue was measured by the FACIT Fatigue scale and PROMIS Fatigue SF1 measure at baseline, week 10, and week 22...
June 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29220298/gastrointestinal-stromal-tumors
#20
Margaret von Mehren, Heikki Joensuu
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers. GISTs occur throughout the intestinal tract, and most harbor an activating mutation in either KIT or platelet-derived growth factor A ( PDGFRA). Diagnosis is made using immunohistochemistry, but molecular testing with mutation analysis is paramount for selection of appropriate therapy. Most small GISTs are cured with surgery. Tyrosine kinase inhibitor (TKI) therapy has led to substantial improvements in survival, both for patients with localized GIST and those with advanced disease...
January 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
110017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"